← Back to Search

Stem Cell Therapy

Group D for Acute Lymphoblastic Leukemia (HPDSC Trial)

Phase 1
Waitlist Available
Led By Mitchell S Cairo, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.

Eligible Conditions
  • Acute Lymphoblastic Leukemia
  • Amegakaryocytic Thrombocytopenia
  • Wolman Disease
  • Metachromatic Leukodystrophy
  • Krabbe Disease
  • Gaucher Disease
  • Aplastic Anemia
  • Adrenoleukodystrophy
  • Fucosidosis
  • Maroteaux-Lamy Syndrome
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Batten Disease
  • Diamond-Blackfan Anemia
  • Niemann-Pick Disease
  • Hurler Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety
Secondary study objectives
donor chimerism

Trial Design

4Treatment groups
Experimental Treatment
Group I: Group DExperimental Treatment1 Intervention
double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
Group II: Group CExperimental Treatment1 Intervention
unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
Group III: Group BExperimental Treatment1 Intervention
unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
Group IV: Group AExperimental Treatment1 Intervention
related cord blood with ≥3/6 HLA match to the patient and related HPDSC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Human Placental Derived Stem Cell
2013
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
70 Previous Clinical Trials
6,090 Total Patients Enrolled
Mitchell S Cairo, MDPrincipal InvestigatorNew York Medical College
14 Previous Clinical Trials
1,125 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top